Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1219591-97-5Pazopanib-D3

● Auf Lager

Katalog-Nr.::	DVE002130
CAS-Nr.::	1219591-97-5
Summenformel::	C21H20D3N7O2S
Molare Masse::	440.5 g/mol

Wie können wir helfen?

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1219591-97-5

Parent drug

Pazopanib

IUPAC-Name

5-((4-((2,3-Dimethyl-2H-indazol-6-yl)(methyl-d3)amino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

CC1=C(C=C(C=C1)NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C([2H])([2H])[2H])=N2)S(=O)(N)=O

InChI

InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)/i3D3

Beschreibung

Pazopanib-D3 impurity (CAS 1219591-97-5) is a deuterated isotopic variant of pazopanib characterized by defined deuterium incorporation and a predictable mass shift relative to the protio compound. This impurity exhibits similar chromatographic retention with minor isotope effects that can affect peak resolution in LC and LC-MS workflows. Analytical identification relies on HRMS and 1H/2H NMR to confirm isotopic enrichment and position of substitution, while forced-degradation studies assess stability under acidic, basic and oxidative conditions. Control strategies include specification limits, validated LC-MS methods for quantitation, and tightly controlled storage to prevent isotopic exchange or degradation.